Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPHEDRINE SULFATE vs ANGIOTENSIN ll ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Treatment of hypotension during spinal anesthesia,Bronchodilation in asthma (less common),Nasal congestion (topical use),Off-label: Treatment of shock, myasthenia gravis (with neostigmine)
Treatment of hypotension in adults with septic or other distributive shock (FDA approved)
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Ephedrine is metabolized primarily by oxidative deamination via monoamine oxidase (MAO) and also by N-demethylation via CYP450 isoenzymes, though specific CYP enzymes are not well characterized. It has a half-life of 3–6 hours.
Primarily metabolized by aminopeptidases and other peptidases in plasma and tissues, with minimal hepatic involvement.
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; p H-dependent; acidic urine enhances elimination.
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
~20-30% bound, primarily to albumin.
Approximately 30% bound to plasma proteins, primarily albumin.
~2-3 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier.
Approximately 0.3-0.5 L/kg; indicates distribution mainly in extracellular fluid.
Oral: ~85% (first-pass metabolism minimal); IM/SC: nearly 100%.
Intravenous: 100%; subcutaneous/intramuscular: not well absorbed due to rapid local metabolism; oral: negligible (<1%) due to extensive first-pass metabolism.
GFR 10-50 m L/min: administer 75% of normal dose every 6 hours. GFR <10 m L/min: administer 50% of normal dose every 6 hours.
No specific dose adjustment required for renal impairment. Use caution in patients with renal artery stenosis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use or use with extreme caution, reduce dose by 75%.
No specific dose adjustment required for hepatic impairment.
Oral: 3 mg/kg/day divided every 4-6 hours. Parenteral: 0.2-0.3 mg/kg/dose intramuscularly or subcutaneously every 4-6 hours; intravenous: 0.05-0.2 mg/kg/dose every 5-10 minutes as needed.
Intravenous infusion: 0.5-20 ng/kg/min titrated to effect. Safety and efficacy not established in neonates.
Initiate at lower doses (e.g., 25 mg orally every 4-6 hours) due to increased sensitivity and risk of CNS stimulation and cardiovascular effects; monitor blood pressure and heart rate closely.
Start at lower end of dosing range (1-5 ng/kg/min) due to potential for decreased renal function and increased sensitivity.
None.
No boxed warnings.
Cardiovascular effects: hypertension, tachycardia, arrhythmias,Central nervous system stimulation: anxiety, insomnia, tremor,Tachyphylaxis with repeated use,Exacerbation of narrow-angle glaucoma,Use in patients with cardiovascular disease, hyperthyroidism, diabetes, or prostatic hypertrophy requires caution
Thrombotic and thromboembolic events: Increased risk of venous and arterial thromboembolic events, including deep vein thrombosis, pulmonary embolism, and myocardial infarction.,Ischemic events: May cause cardiac ischemia and reduce cardiac output; use with caution in patients with coronary artery disease.,Vascular thrombosis: High risk of vascular thrombosis in patients with a history of thrombosis or hypercoagulable states.,Use in hypovolemia: Correct hypovolemia before administration to avoid exacerbation of vasoconstriction.,Pregnancy: May cause fetal harm; avoid use in pregnant women unless potential benefit outweighs risk.
Hypersensitivity to ephedrine or other sympathomimetics,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors (MAOIs),Narrow-angle glaucoma,Pheochromocytoma,Hypertrophic obstructive cardiomyopathy
Hypersensitivity to angiotensin II acetate or any component of the formulation,No absolute contraindications listed by the manufacturer; however, use is avoided in patients with uncorrected hypovolemia and those with a history of thromboembolic events.
Avoid excessive caffeine intake (coffee, tea, colas) as it may increase stimulant effects and risk of cardiovascular side effects. Limit or avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. No other significant food interactions.
No food interactions specific to angiotensin II acetate. Maintain a balanced diet as tolerated. Avoid excessive salt intake unless directed otherwise, as it may counteract the medication's effect on blood pressure.
Ephedrine sulfate crosses the placenta. Use in the first trimester is associated with a small increased risk of gastroschisis. In the second and third trimesters, it may cause fetal tachycardia and uterine artery vasoconstriction, potentially leading to reduced uteroplacental blood flow. Animal studies have shown embryotoxicity at high doses.
First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, and death. Use contraindicated in pregnancy.
Ephedrine is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 2.5. At therapeutic doses, it is unlikely to cause adverse effects in the infant, but irritability and disturbed sleep have been reported. Caution is advised.
No data on M/P ratio. Likely excreted in breast milk. Avoid breastfeeding due to unknown risks to neonate.
Pregnancy does not significantly alter ephedrine pharmacokinetics. However, due to increased plasma volume and renal blood flow, the volume of distribution may be slightly increased. No routine dose adjustment is required, but careful titration is recommended due to altered vascular reactivity.
No dose adjustment recommended if used; however, if inadvertently exposed, discontinue drug. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may lower drug levels, but no established dose adjustment.
Ephedrine sulfate is a direct and indirect sympathomimetic used primarily for hypotension during spinal/epidural anesthesia. It crosses the placenta and may cause fetal tachycardia. Avoid in patients with narrow-angle glaucoma, hyperthyroidism, or pheochromocytoma. Tachyphylaxis can develop with repeated doses. Use with caution in patients with cardiovascular disease, hypertension, or diabetes. Monitor blood pressure and heart rate closely.
ANGIOTENSIN II ACETATE is a vasoconstrictor used for refractory hypotension in distributive shock. Administer via central line to avoid extravasation, which can cause severe tissue ischemia. Monitor blood pressure every 5 minutes during titration. Discontinue other vasopressors if possible to avoid additive arrhythmogenic effects. Use with caution in patients with coronary artery disease or previous myocardial infarction due to increased oxygen demand. Taper gradually to avoid rebound hypotension.
Do not take this medication without your doctor's approval if you have high blood pressure, heart disease, or thyroid problems.,Avoid using other stimulants or decongestants while on this medication.,Report any chest pain, irregular heartbeat, or shortness of breath to your healthcare provider immediately.,This medication may cause dizziness or nervousness; avoid driving or operating heavy machinery until you know how it affects you.,If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using ephedrine.
This medication is given intravenously in the hospital to raise very low blood pressure. You will be closely monitored during treatment.,Inform your healthcare provider immediately if you experience chest pain, difficulty breathing, or irregular heartbeat.,Avoid sudden position changes to prevent dizziness, as blood pressure may fluctuate.,Report any pain, swelling, or color changes at the injection site, which could indicate medication leakage.,You may need regular blood tests to monitor kidney function and electrolyte levels.
"Sevoflurane, a volatile halogenated anesthetic, sensitizes the myocardium to the arrhythmogenic effects of catecholamines such as ephedrine. This synergistic action can precipitate ventricular arrhythmias, including premature ventricular contractions, bigeminy, or, rarely, ventricular tachycardia, particularly in patients with underlying cardiac disease or electrolyte imbalances. Clinically, this interaction may manifest as intraoperative arrhythmias, hemodynamic instability, or increased perioperative cardiac risk."
"The combined use of ephedrine, a direct and indirect sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors, with nylidrin, a beta-adrenergic agonist that primarily targets beta-2 receptors to induce peripheral vasodilation, can lead to additive beta-adrenergic stimulation. This synergy increases the risk of cardiovascular adverse effects, including tachycardia, hypertension, myocardial ischemia, and arrhythmias, particularly in patients with pre-existing cardiovascular disease."
"Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), increases systemic norepinephrine levels by inhibiting its reuptake, leading to enhanced sympathetic tone. Ephedrine directly stimulates alpha- and beta-adrenergic receptors and also promotes norepinephrine release from presynaptic terminals. The concurrent elevation of norepinephrine from both mechanisms can synergistically increase heart rate and blood pressure, potentially resulting in severe tachycardia, hypertension, and elevated risk of arrhythmias or myocardial ischemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPHEDRINE SULFATE vs ANGIOTENSIN ll ACETATE, answered by our medical review team.
EPHEDRINE SULFATE is a Vasopressor that works by Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.. ANGIOTENSIN ll ACETATE is a Vasopressor that works by Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPHEDRINE SULFATE and ANGIOTENSIN ll ACETATE depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPHEDRINE SULFATE is: 50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.. The standard adult dose of ANGIOTENSIN ll ACETATE is: Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPHEDRINE SULFATE and ANGIOTENSIN ll ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPHEDRINE SULFATE is classified as Category C. Ephedrine sulfate crosses the placenta. Use in the first trimester is associated with a small increased risk of gastroschisis. In the second and third trimesters, it may cause feta. ANGIOTENSIN ll ACETATE is classified as Category C. First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, sku. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.